Evidence map›Paper›PMID 39323378›Full record

ArticleJournal of extracellular vesicles2024

Scalable production of siRNA-encapsulated extracellular vesicles for the inhibition of KRAS-mutant cancer using acoustic shock waves.

Hyo Kyeong Kim, Yujeong Choi, Kyoung Hwa Kim, Yeongju Byun, Tae Hee Kim, Jae Hwan Kim, Shung Hyun An, DaeHo Bae, Myeong Kwan Choi, Minyoung Lee and 4 more

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Extracellular Vesicle-Based Drug Delivery Systems in Cancer Therapy.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hyo Kyeong KimExollence Co., Ltd., Seoul, Republic of Korea.ORCID 0000-0002-3978-0783
Yujeong ChoiExollence Co., Ltd., Seoul, Republic of Korea.
Kyoung Hwa KimExollence Co., Ltd., Seoul, Republic of Korea.
Yeongju ByunExollence Co., Ltd., Seoul, Republic of Korea.
Tae Hee KimExollence Co., Ltd., Seoul, Republic of Korea.
Jae Hwan KimExollence Co., Ltd., Seoul, Republic of Korea.
Shung Hyun AnExollence Co., Ltd., Seoul, Republic of Korea.
DaeHo BaeExollence Co., Ltd., Seoul, Republic of Korea.
Myeong Kwan ChoiExollence Co., Ltd., Seoul, Republic of Korea.
Minyoung LeeExollence Co., Ltd., Seoul, Republic of Korea.
Gwansuk KangDivision of Gastroenterology and Hepatology, School of Medicine, Stanford University, Stanford, California, USA.
Jihwa ChungExollence Co., Ltd., Seoul, Republic of Korea.
Seok-Hyun KimExollence Co., Ltd., Seoul, Republic of Korea.
Kihwan KwonExollence Co., Ltd., Seoul, Republic of Korea.

Funding

Korea Drug Development Fund RS-2023-00282594Korean Ministry of Health and Welfare HV22C0030Korea Technology and Information Promotion Agency for SMEs RS-2023-00280797Korea Technology and Information Promotion Agency for SMEs S3313778National Research Foundation of Korea 2023M3A9G106060112
6 · The paper itself

Abstract

Extracellular vesicles (EVs) have emerged as a potential delivery vehicle for nucleic-acid-based therapeutics, but challenges related to their large-scale production and cargo-loading efficiency have limited their therapeutic potential. To address these issues, we developed a novel "shock wave extracellular vesicles engineering technology" (SWEET) as a non-genetic, scalable manufacturing strategy that uses shock waves (SWs) to encapsulate siRNAs in EVs. Here, we describe the use of the SWEET platform to load large quantities of KRAS

Indexed as

Extracellular VesiclesProto-Oncogene Proteins p21(ras)RNA, Small InterferingAnimalsCarcinoma, Non-Small-Cell LungCattleCell Line, TumorHumansLung NeoplasmsMiceMutationXenograft Model Antitumor AssaysKRAS protein, humanProto-Oncogene Proteins p21(ras)RNA, Small Interferinganti‐cancer effectsbovine‐milk‐derived extracellular vesiclesgene deliverynon‐small cell lung cancernucleic‐acid‐based therapeuticsscalable productionshock wavesiRNA against KRAS G12C mutant

Identifiers

PMID39323378
PMCPMC11424982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.